2.1
Zanubrutinib (Brukinsa, BeiGene) is indicated for 'the treatment of adult patients with chronic lymphocytic leukaemia'.
Zanubrutinib (Brukinsa, BeiGene) is indicated for 'the treatment of adult patients with chronic lymphocytic leukaemia'.
The dosage schedule is available in the summary of product characteristics for zanubrutinib.
A 120‑pack of 80‑mg zanubrutinib capsules costs £4,928.65 (excluding VAT; BNF online accessed September 2023). The company has a commercial arrangement. This makes zanubrutinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.